Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges

被引：8

作者：

D'Aiello, Angelica ^{[1
,6
]}

Stiles, Brendon ^{[2
]}

Ohri, Nitin ^{[3
]}

Levy, Benjamin ^{[4
]}

Cohen, Perry ^{[5
]}

Halmos, Balazs ^{[1
,6
]}

机构：

[1] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, Bronx, NY USA

[2] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Div Thorac Surg & Surg Oncol, Bronx, NY USA

[3] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Radiat Oncol, Bronx, NY USA

[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA

[5] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Pathol, Div Anat & Clin Pathol, Bronx, NY USA

[6] Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USA

来源：

CLINICAL LUNG CANCER | 2024年 / 25卷 / 03期

关键词：

Adjuvant; Immunotherapy; Lung cancer; NSCLC; Neoadjuvant; NEOADJUVANT ATEZOLIZUMAB; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; PLUS CHEMOTHERAPY; OPEN-LABEL; RADIOTHERAPY; PEMBROLIZUMAB; DURVALUMAB; SURGERY; NSCLC;

D O I：

10.1016/j.cllc.2024.02.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting. As more results read out from ongoing per ioperative clinical tr ials, navigating treatment options will likely become increasingly complex for the practicing oncologist. In this paper, we distill key outcomes from major perioperative trials and highlight current knowledge gaps. In addition, we provide practical considerations for incorporating perioperative immunotherapy into the clinical management of operable NSCLC.

引用

页码：197 / 214

页数：18

共 77 条

[41] Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis [J].

Lee, Chee Khoon ;

Man, Johnathan ;

Lord, Sally ;

Links, Matthew ;

Gebski, Val ;

Mok, Tony ;

Yang, James Chih-Hsin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :403-407

[42] A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC [J].

Lemmon, Christopher A. ;

Videtic, Gregory M. M. ;

Murthy, Sudish ;

Stephans, Kevin L. ;

Shapiro, Marc ;

Ahmad, Usman ;

Raymond, Daniel ;

Velcheti, Vamsidhar ;

Bribriesco, Alejandro ;

Jia, Xuefei ;

Stevenson, James ;

Pennell, Nathan A. .

JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (07)

[43] Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial [J].

Lu, Shun ;

Zhang, Wei ;

Wu, Lin ;

Wang, Wenxiang ;

Zhang, Peng .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (03) :201-211

[44] Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. [J].

Lu, Shun ;

Wu, Lin ;

Zhang, Wei ;

Zhang, Peng ;

Wang, Wenxiang ;

Fang, Wentao ;

Xing, Wenqun ;

Chen, Qixun ;

Mei, Jiandong ;

Yang, Lin ;

Tan, Lijie ;

Sun, Xiaohong ;

Xu, Shidong ;

Hu, Xiaohua ;

Yu, Guohua ;

Yu, Dongliang ;

Shan, Jinlu ;

Yang, Nong ;

Chen, Yuping ;

Tian, Hui .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) :425126-425126

[45] FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC [J].

Mathieu, Luckson N. ;

Larkins, Erin ;

Sinha, Arup K. ;

Mishra-Kalyani, Pallavi S. ;

Jafri, Samina ;

Kalavar, Shyam ;

Ghosh, Soma ;

Goldberg, Kirsten B. ;

Pazdur, Richard ;

Beaver, Julia A. ;

Singh, Harpreet .

CLINICAL CANCER RESEARCH, 2023, 29 (16) :2973-2978

[46] Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer [J].

Moding, Everett J. ;

Liu, Yufei ;

Nabet, Barzin Y. ;

Chabon, Jacob J. ;

Chaudhuri, Aadel A. ;

Hui, Angela B. ;

Bonilla, Rene F. ;

Ko, Ryan B. ;

Yoo, Christopher H. ;

Gojenola, Linda ;

Jones, Carol D. ;

He, Jianzhong ;

Qiao, Yawei ;

Xu, Ting ;

Heymach, John V. ;

Tsao, Anne ;

Liao, Zhongxing ;

Gomez, Daniel R. ;

Das, Millie ;

Padda, Sukhmani K. ;

Ramchandran, Kavitha J. ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Loo, Billy W., Jr. ;

Lin, Steven H. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

NATURE CANCER, 2020, 1 (02) :176-+

[47] Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC [J].

Naidoo, Jarushka ;

Antonia, Scott ;

Wu, Yi-Long ;

Cho, Byoung Chul ;

Thiyagarajah, Piruntha ;

Mann, Helen ;

Newton, Michael ;

Faivre-Finn, Corinne .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) :657-663

[48] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial [J].

O'Brien, Mary ;

Paz-Ares, Luis ;

Marreaud, Sandrine ;

Dafni, Urania ;

Oselin, Kersti ;

Havel, Libor ;

Esteban, Emilio ;

Isla, Dolores ;

Martinez-Marti, Alex ;

Faehling, Martin ;

Tsuboi, Masahiro ;

Lee, Jong-Seok ;

Nakagawa, Kazuhiko ;

Yang, Jing ;

Samkari, Ayman ;

Keller, Steven M. ;

Mauer, Murielle ;

Jha, Nitish ;

Stahel, Rolf ;

Besse, Benjamin ;

Peters, Solange .

LANCET ONCOLOGY, 2022, 23 (10) :1274-1286

[49]

Patel SP, 2023, NEW ENGL J MED, V388, P813, DOI 10.1056/NEJMoa2211437

[50] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial [J].

Paz-Ares, Luis G. ;

Ramalingam, Suresh S. ;

Ciuleanu, Tudor-Eliade ;

Lee, Jong-Seok ;

Urban, Laszlo ;

Caro, Reyes Bernabe ;

Park, Keunchil ;

Sakai, Hiroshi ;

Ohe, Yuichiro ;

Nishio, Makoto ;

Audigier-Valette, Clarisse ;

Burgers, Jacobus A. ;

Pluzanski, Adam ;

Sangha, Randeep ;

Gallardo, Carlos ;

Takeda, Masayuki ;

Linardou, Helena ;

Lupinacci, Lorena ;

Lee, Ki Hyeong ;

Caserta, Claudia ;

Provencio, Mariano ;

Carcereny, Enric ;

Otterson, Gregory A. ;

Schenker, Michael ;

Zurawski, Bogdan ;

Alexandru, Aurelia ;

Vergnenegre, Alain ;

Raimbourg, Judith ;

Feeney, Kynan ;

Kim, Sang-We ;

Borghaei, Hossein ;

O'Byrne, Kenneth John ;

Hellmann, Matthew D. ;

Memaj, Arteid ;

Nathan, Faith Ellen ;

Bushong, Judith ;

Phuong Tran ;

Brahmer, Julie R. ;

Reck, Martin .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (02) :289-308

← 1 2 3 4 5 6 7 8 →